Krishnamoorthy V, Hamdani F, Shukla P, Rao R, Anaitullah S, Biligiri K
Life Sci Alliance. 2024; 8(3.
PMID: 39741006
PMC: 11707394.
DOI: 10.26508/lsa.202402871.
Pierson Smela M, Pepe V, Lubbe S, Kiskinis E, Church G
Stem Cell Reports. 2024; 19(10):1505-1515.
PMID: 39270651
PMC: 11561455.
DOI: 10.1016/j.stemcr.2024.08.004.
Madrid M, Lakshmipathy U, Zhang X, Bharti K, Wall D, Sato Y
Cytotherapy. 2024; 26(11):1382-1399.
PMID: 38958627
PMC: 11471376.
DOI: 10.1016/j.jcyt.2024.05.022.
Park J, Bae S, Yun J, Kim S, Park M
Int J Mol Sci. 2024; 25(2).
PMID: 38256178
PMC: 10815998.
DOI: 10.3390/ijms25021101.
Nogueira I, Costa G, Lacerda S
Animals (Basel). 2024; 14(2).
PMID: 38254390
PMC: 10812705.
DOI: 10.3390/ani14020220.
SeqVerify: An accessible analysis tool for cell line genomic integrity, contamination, and gene editing outcomes.
Pierson Smela M, Pepe V, Church G
bioRxiv. 2023; .
PMID: 37829615
PMC: 10565884.
DOI: 10.1101/2023.09.27.559766.
Enhanced Expansion of Human Pluripotent Stem Cells and Somatic Cell Reprogramming Using Defined and Xeno-Free Culture Conditions.
Timilsina S, McCandliss K, Trivedi E, Villa-Diaz L
Bioengineering (Basel). 2023; 10(9).
PMID: 37760101
PMC: 10525589.
DOI: 10.3390/bioengineering10090999.
Xeno-free generation of human induced pluripotent stem cells from donor-matched fibroblasts isolated from dermal and oral tissues.
Ali H, Suliman S, Osman T, Carrasco M, Bruland O, Costea D
Stem Cell Res Ther. 2023; 14(1):199.
PMID: 37559144
PMC: 10410907.
DOI: 10.1186/s13287-023-03403-7.
Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.
Dhanjal D, Singh R, Sharma V, Nepovimova E, Adam V, Kuca K
Curr Med Chem. 2023; 31(13):1646-1690.
PMID: 37138422
DOI: 10.2174/0929867330666230503144619.
Allogenic Synovia-Derived Mesenchymal Stem Cells for Treatment of Equine Tendinopathies and Desmopathies-Proof of Concept.
Leal Reis I, Lopes B, Sousa P, Sousa A, Branquinho M, Caseiro A
Animals (Basel). 2023; 13(8).
PMID: 37106875
PMC: 10135243.
DOI: 10.3390/ani13081312.
TPX2 Amplification-Driven Aberrant Mitosis in Culture Adapted Human Embryonic Stem Cells with gain of 20q11.21.
Jeong H, Go Y, Shin J, Kim Y, Cho M, Gwon D
Stem Cell Rev Rep. 2023; 19(5):1466-1481.
PMID: 36862329
DOI: 10.1007/s12015-023-10514-4.
In vitro germ cell induction from fertile and infertile monozygotic twin research participants.
Pandolfi E, Hsu F, Duhon M, Zheng Y, Goldsmith S, Fu J
Cell Rep Med. 2022; 3(10):100782.
PMID: 36260988
PMC: 9589117.
DOI: 10.1016/j.xcrm.2022.100782.
Treating intrauterine adhesion using conditionally reprogrammed physiological endometrial epithelial cells.
Xia S, Wu M, Zhou X, Zhang X, Ye L, Zhang K
Stem Cell Res Ther. 2022; 13(1):178.
PMID: 35505443
PMC: 9066886.
DOI: 10.1186/s13287-022-02860-w.
Novel cell sources for bone regeneration.
Li C, Mills Z, Zheng Z
MedComm (2020). 2021; 2(2):145-174.
PMID: 34766140
PMC: 8491221.
DOI: 10.1002/mco2.51.
A library of induced pluripotent stem cells from clinically well-characterized, diverse healthy human individuals.
Schaniel C, Dhanan P, Hu B, Xiong Y, Raghunandan T, Gonzalez D
Stem Cell Reports. 2021; 16(12):3036-3049.
PMID: 34739849
PMC: 8693622.
DOI: 10.1016/j.stemcr.2021.10.005.
Neural is Fundamental: Neural Stemness as the Ground State of Cell Tumorigenicity and Differentiation Potential.
Cao Y
Stem Cell Rev Rep. 2021; 18(1):37-55.
PMID: 34714532
DOI: 10.1007/s12015-021-10275-y.
Non-immunogenic Induced Pluripotent Stem Cells, a Promising Way Forward for Allogenic Transplantations for Neurological Disorders.
Frederiksen H, Doehn U, Tveden-Nyborg P, Freude K
Front Genome Ed. 2021; 2:623717.
PMID: 34713244
PMC: 8525385.
DOI: 10.3389/fgeed.2020.623717.
RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy.
Magdy T, Jiang Z, Jouni M, Fonoudi H, Lyra-Leite D, Jung G
Cell Stem Cell. 2021; 28(12):2076-2089.e7.
PMID: 34525346
PMC: 8642268.
DOI: 10.1016/j.stem.2021.08.006.
Alagille Syndrome: Diagnostic Challenges and Advances in Management.
Ayoub M, Kamath B
Diagnostics (Basel). 2020; 10(11).
PMID: 33172025
PMC: 7694636.
DOI: 10.3390/diagnostics10110907.
Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product.
Jha B, Farnoodian M, Bharti K
Stem Cells Transl Med. 2020; 10(2):198-208.
PMID: 32946199
PMC: 7848308.
DOI: 10.1002/sctm.20-0242.